Log in

NYSE:MCKMcKesson Competitors & Alternatives

$143.02
+2.13 (+1.51 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$140.85
Now: $143.02
$143.88
50-Day Range
$140.89
MA: $153.49
$164.68
52-Week Range
$112.60
Now: $143.02
$172.18
Volume958,400 shs
Average Volume1.16 million shs
Market Capitalization$23.19 billion
P/E Ratio27.88
Dividend Yield1.15%
Beta0.84

Competitors

McKesson (NYSE:MCK) Vs. CELG, VRTX, BDX, REGN, ISRG, and SYK

Should you be buying MCK stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to McKesson, including Celgene (CELG), Vertex Pharmaceuticals (VRTX), Becton Dickinson and (BDX), Regeneron Pharmaceuticals (REGN), Intuitive Surgical (ISRG), and Stryker (SYK).

McKesson (NYSE:MCK) and Celgene (NASDAQ:CELG) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares McKesson and Celgene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
McKesson0.39%41.07%4.47%
Celgene34.63%78.15%18.54%

Analyst Recommendations

This is a summary of recent ratings for McKesson and Celgene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
McKesson051002.67
Celgene06002.00

McKesson currently has a consensus price target of $172.7143, indicating a potential upside of 20.76%. Celgene has a consensus price target of $105.60, indicating a potential downside of 2.44%. Given McKesson's stronger consensus rating and higher probable upside, equities research analysts plainly believe McKesson is more favorable than Celgene.

Risk and Volatility

McKesson has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Celgene has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Institutional & Insider Ownership

79.2% of McKesson shares are owned by institutional investors. Comparatively, 71.7% of Celgene shares are owned by institutional investors. 0.3% of McKesson shares are owned by insiders. Comparatively, 0.4% of Celgene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares McKesson and Celgene's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$231.05 billion0.10$900 million$14.959.57
Celgene$15.28 billion5.04$4.05 billion$7.6114.22

Celgene has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Celgene, indicating that it is currently the more affordable of the two stocks.

McKesson (NYSE:MCK) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares McKesson and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
McKesson0.39%41.07%4.47%
Vertex Pharmaceuticals31.35%25.69%18.50%

Analyst Recommendations

This is a summary of recent ratings for McKesson and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
McKesson051002.67
Vertex Pharmaceuticals082012.76

McKesson currently has a consensus price target of $172.7143, indicating a potential upside of 20.76%. Vertex Pharmaceuticals has a consensus price target of $285.1154, indicating a potential downside of 3.17%. Given McKesson's higher probable upside, equities research analysts plainly believe McKesson is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

McKesson has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

79.2% of McKesson shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.3% of McKesson shares are owned by insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares McKesson and Vertex Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$231.05 billion0.10$900 million$14.959.57
Vertex Pharmaceuticals$4.16 billion18.34$1.18 billion$4.2968.64

Vertex Pharmaceuticals has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats McKesson on 11 of the 15 factors compared between the two stocks.

McKesson (NYSE:MCK) and Becton Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares McKesson and Becton Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
McKesson0.39%41.07%4.47%
Becton Dickinson and6.10%15.75%6.37%

Dividends

McKesson pays an annual dividend of $1.64 per share and has a dividend yield of 1.1%. Becton Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.2%. McKesson pays out 11.0% of its earnings in the form of a dividend. Becton Dickinson and pays out 27.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. McKesson has increased its dividend for 7 consecutive years and Becton Dickinson and has increased its dividend for 48 consecutive years. Becton Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of recent ratings for McKesson and Becton Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
McKesson051002.67
Becton Dickinson and07902.56

McKesson currently has a consensus price target of $172.7143, indicating a potential upside of 20.76%. Becton Dickinson and has a consensus price target of $276.0667, indicating a potential upside of 7.26%. Given McKesson's stronger consensus rating and higher probable upside, equities research analysts plainly believe McKesson is more favorable than Becton Dickinson and.

Volatility & Risk

McKesson has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Becton Dickinson and has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Institutional and Insider Ownership

79.2% of McKesson shares are held by institutional investors. Comparatively, 85.4% of Becton Dickinson and shares are held by institutional investors. 0.3% of McKesson shares are held by insiders. Comparatively, 0.1% of Becton Dickinson and shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares McKesson and Becton Dickinson and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$231.05 billion0.10$900 million$14.959.57
Becton Dickinson and$17.29 billion4.04$1.23 billion$11.6822.04

Becton Dickinson and has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Becton Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton Dickinson and beats McKesson on 9 of the 17 factors compared between the two stocks.

McKesson (NYSE:MCK) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings for McKesson and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
McKesson051002.67
Regeneron Pharmaceuticals0121412.59

McKesson currently has a consensus price target of $172.7143, indicating a potential upside of 20.76%. Regeneron Pharmaceuticals has a consensus price target of $573.2593, indicating a potential downside of 7.67%. Given McKesson's stronger consensus rating and higher probable upside, equities research analysts plainly believe McKesson is more favorable than Regeneron Pharmaceuticals.

Risk and Volatility

McKesson has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Valuation and Earnings

This table compares McKesson and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$231.05 billion0.10$900 million$14.959.57
Regeneron Pharmaceuticals$7.86 billion8.69$2.12 billion$21.4728.92

Regeneron Pharmaceuticals has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares McKesson and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
McKesson0.39%41.07%4.47%
Regeneron Pharmaceuticals28.56%24.94%18.81%

Institutional & Insider Ownership

79.2% of McKesson shares are owned by institutional investors. Comparatively, 68.1% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.3% of McKesson shares are owned by insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats McKesson on 9 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Intuitive Surgical and McKesson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical461202.36
McKesson051002.67

Intuitive Surgical currently has a consensus target price of $571.1176, indicating a potential downside of 0.83%. McKesson has a consensus target price of $172.7143, indicating a potential upside of 20.76%. Given McKesson's stronger consensus rating and higher possible upside, analysts plainly believe McKesson is more favorable than Intuitive Surgical.

Volatility & Risk

Intuitive Surgical has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Valuation & Earnings

This table compares Intuitive Surgical and McKesson's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion15.00$1.38 billion$9.9557.88
McKesson$231.05 billion0.10$900 million$14.959.57

Intuitive Surgical has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intuitive Surgical and McKesson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical30.11%17.40%14.87%
McKesson0.39%41.07%4.47%

Institutional & Insider Ownership

87.2% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 79.2% of McKesson shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by company insiders. Comparatively, 0.3% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Intuitive Surgical beats McKesson on 9 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Stryker and McKesson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker271612.62
McKesson051002.67

Stryker currently has a consensus target price of $215.20, indicating a potential upside of 20.97%. McKesson has a consensus target price of $172.7143, indicating a potential upside of 20.76%. Given Stryker's higher possible upside, analysts plainly believe Stryker is more favorable than McKesson.

Volatility & Risk

Stryker has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Valuation & Earnings

This table compares Stryker and McKesson's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion4.48$2.08 billion$8.2621.54
McKesson$231.05 billion0.10$900 million$14.959.57

Stryker has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.3%. McKesson pays an annual dividend of $1.64 per share and has a dividend yield of 1.1%. Stryker pays out 27.8% of its earnings in the form of a dividend. McKesson pays out 11.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 9 consecutive years and McKesson has increased its dividend for 7 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Stryker and McKesson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker14.47%24.90%11.10%
McKesson0.39%41.07%4.47%

Institutional and Insider Ownership

71.2% of Stryker shares are owned by institutional investors. Comparatively, 79.2% of McKesson shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 0.3% of McKesson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Stryker beats McKesson on 11 of the 17 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Celgene logo
CELG
Celgene
1.7$108.24+0.0%$77.04 billion$15.28 billion14.22
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
1.4$294.45+0.3%$76.34 billion$4.16 billion51.03
Becton Dickinson and logo
BDX
Becton Dickinson and
1.9$257.37+0.5%$69.79 billion$17.29 billion77.52
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.4$620.86+3.2%$68.31 billion$7.86 billion31.20
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.6$575.87+0.2%$67.16 billion$4.48 billion49.60
Stryker logo
SYK
Stryker
2.3$177.89+0.1%$66.68 billion$14.88 billion31.26
Zoetis logo
ZTS
Zoetis
1.9$137.10+0.4%$65.11 billion$6.26 billion40.93
Anthem logo
ANTM
Anthem
2.7$255.00+0.0%$64.29 billion$104.21 billion13.81Analyst Report
Analyst Revision
TAK
Takeda Pharmaceutical
1.7$17.27+0.1%$54.45 billion$30.20 billion123.37
Illumina logo
ILMN
Illumina
1.4$370.25+0.6%$54.43 billion$3.54 billion58.31
Humana logo
HUM
Humana
1.9$381.58+0.4%$50.45 billion$64.89 billion19.59Analyst Revision
Boston Scientific logo
BSX
Boston Scientific
2.3$34.68+0.5%$48.53 billion$10.74 billion11.41
Biogen logo
BIIB
Biogen
1.9$278.88+0.1%$45.51 billion$14.38 billion8.61Analyst Report
Baxter International logo
BAX
Baxter International
1.9$85.23+0.5%$43.23 billion$11.36 billion25.75
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.7$67.82+0.6%$42.03 billion$4.35 billion38.90Insider Selling
DexCom logo
DXCM
DexCom
1.5$439.64+0.2%$40.60 billion$1.48 billion276.50Insider Selling
Centene logo
CNC
Centene
2.1$62.84+0.7%$36.39 billion$74.64 billion31.74Analyst Revision
HCA Healthcare logo
HCA
HCA Healthcare
2.9$96.72+2.5%$32.65 billion$51.34 billion11.00Analyst Downgrade
Analyst Revision
Seattle Genetics logo
SGEN
Seattle Genetics
1.3$174.35+3.9%$30.18 billion$916.71 million-92.74Insider Selling
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.3$338.25+0.9%$28.73 billion$2.41 billion67.65
ResMed logo
RMD
ResMed
1.2$192.09+0.8%$27.79 billion$2.61 billion54.42
ALC
Alcon
1.5$56.89+0.0%$27.77 billion$7.51 billion-45.51
Fresenius Medical Care AG & Co. logo
FMS
Fresenius Medical Care AG & Co.
1.4$42.49+0.3%$25.35 billion$19.58 billion19.05
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.2$119.43+1.5%$24.65 billion$7.98 billion65.98
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.3$108.82+0.3%$24.03 billion$4.99 billion10.25Analyst Revision
MRNA
Moderna
1.4$62.61+3.8%$23.24 billion$60.21 million-41.74Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.7$126.06+0.6%$22.80 billion$1.70 billion206.66
GMAB
Genmab A/S
1.2$34.92+1.9%$22.80 billion$804.57 million18.77
Incyte logo
INCY
Incyte
1.4$104.76+3.0%$22.77 billion$2.16 billion-59.86Analyst Upgrade
Align Technology logo
ALGN
Align Technology
1.9$273.29+0.3%$21.53 billion$2.41 billion11.46
Cerner logo
CERN
Cerner
2.1$69.93+0.4%$21.28 billion$5.69 billion43.43
AmerisourceBergen logo
ABC
AmerisourceBergen
2.2$97.05+0.7%$19.74 billion$179.59 billion12.77
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.5$162.25+2.2%$18.72 billion$219.75 million-20.21Insider Selling
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.6$232.23+1.6%$17.09 billion$1.84 billion67.12
Teladoc Health logo
TDOC
Teladoc Health
1.3$228.98+0.2%$17.05 billion$553.31 million-169.61Insider Selling
Smith & Nephew logo
SNN
Smith & Nephew
1.7$38.51+0.2%$16.86 billion$5.14 billion18.88Analyst Report
Laboratory Corp. of America logo
LH
Laboratory Corp. of America
1.6$172.68+0.3%$16.78 billion$11.55 billion53.46Insider Selling
Teleflex logo
TFX
Teleflex
1.7$354.78+0.6%$16.47 billion$2.60 billion30.35
BNTX
BioNTech
0.9$70.36+6.8%$15.92 billion$121.63 million-74.06
Quest Diagnostics logo
DGX
Quest Diagnostics
2.0$116.82+0.8%$15.62 billion$7.73 billion20.11
Cooper Companies logo
COO
Cooper Companies
2.7$289.40+0.1%$15.43 billion$2.65 billion42.13
Beigene logo
BGNE
Beigene
1.1$196.03+1.9%$15.25 billion$428.21 million-11.12Analyst Report
Heavy News Reporting
Hologic logo
HOLX
Hologic
1.7$57.70+0.4%$14.90 billion$3.37 billion25.20
Cardinal Health logo
CAH
Cardinal Health
2.4$49.36+1.0%$14.41 billion$145.53 billion-3.51
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$477.66+0.1%$14.16 billion$2.31 billion9.15
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$92.08+0.7%$13.80 billion$876.29 million-118.05Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.7$168.81+0.7%$13.17 billion$380.83 million-19.12
Insulet logo
PODD
Insulet
1.4$207.82+1.7%$13.11 billion$738.20 million2,598.07Analyst Upgrade
BIO.B
Bio-Rad Laboratories
0.7$436.97+0.0%$12.95 billion$2.31 billion8.37
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$11.76+1.3%$12.84 billion$16.89 billion-15.47
This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.